In vitro studies on CLL cell line overexpressing exogenous TRERNA1 showed that TRERNA1 impairs the induction of DNA damage following exposure to chemotherapeutic agents, which may account for poor response to therapy in high-expressing patients [144]. This evidence concerns the gene TRERNA1 and B-cell chronic lymphocytic leukemia.